Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter CD79a Antikörper (AA 202-216)

CD79A Reaktivität: Human, Maus, Ratte, Rind (Kuh), Schwein, Affe FACS, IF, IHC (p) Wirt: Kaninchen Monoclonal IGA-1790R unconjugated Recombinant Antibody
Produktnummer ABIN5646923
  • Target Alle CD79a (CD79A) Antikörper anzeigen
    CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
    Antikörpertyp
    Recombinant Antibody
    Bindungsspezifität
    • 68
    • 25
    • 11
    • 10
    • 8
    • 7
    • 7
    • 6
    • 6
    • 5
    • 5
    • 5
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 202-216
    Reaktivität
    • 190
    • 101
    • 80
    • 51
    • 50
    • 31
    • 28
    • 26
    • 26
    • 26
    • 16
    • 10
    • 5
    • 5
    • 2
    • 1
    Human, Maus, Ratte, Rind (Kuh), Schwein, Affe
    Wirt
    • 103
    • 101
    • 3
    • 1
    Kaninchen
    Klonalität
    • 125
    • 82
    • 1
    Monoklonal
    Konjugat
    • 91
    • 19
    • 16
    • 15
    • 15
    • 8
    • 5
    • 5
    • 5
    • 5
    • 5
    • 5
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Dieser CD79a Antikörper ist unkonjugiert
    Applikation
    • 118
    • 97
    • 63
    • 58
    • 45
    • 24
    • 22
    • 15
    • 10
    • 5
    • 5
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Aufreinigung
    Purified
    Reinheit
    Protein A affinity chromatography
    Immunogen
    Amino acids 202-216 (GTYQDVGSLNIADVQ) were used as the immunogen for the recombinant CD79a antibody.
    Klon
    IGA-1790R
    Isotyp
    IgG kappa
    Top Product
    Discover our top product CD79A Primärantikörper
  • Applikationshinweise
    Optimal dilution of the recombinant CD79a antibody should be determined by the researcher.

    1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,IHC (FFPE): 0.25-0.5 μg/mL for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Konzentration
    1 mg/mL
    Buffer
    1 mg/mL in 1X PBS, BSA free, sodium azide free
    Konservierungsmittel
    Azide free
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store the recombinant CD79a antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
  • Target
    CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))
    Andere Bezeichnung
    CD79a (CD79A Produkte)
    Synonyme
    CD79A antikoerper, Ig-alpha antikoerper, Iga antikoerper, Igalpha antikoerper, Ly-54 antikoerper, Ly54 antikoerper, mb-1 antikoerper, IGA antikoerper, MB-1 antikoerper, IG-alpha antikoerper, CD79a molecule antikoerper, CD79A antigen (immunoglobulin-associated alpha) antikoerper, Cd79a molecule-like antikoerper, CD79A antikoerper, Cd79a antikoerper, Cd79al antikoerper
    Hintergrund
    A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.
    Pathways
    BCR Signaling
Sie sind hier:
Kundenservice